Evidence map›Paper›PMID 41042435›Full record

ReviewEJNMMI radiopharmacy and chemistry2025

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Jun Toyohara, Philipp H Elsinga, Sergio Todde, Xiang-Guo Li, Silvio Aime, Wictor C Szymanski, Nick van der Meulen, Frederik Cleeren, Ralf Schirrmacher, Hua Yang and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jun ToyoharaTokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Philipp H ElsingaUniversity of Groningen, Groningen, The Netherlands.
Sergio ToddeUniversity of Milano-Bicocca, Monza, Italy.
Xiang-Guo LiTurku PET Centre, University of Turku, Turku, Finland.
Silvio AimeIRCCS SDN SynLab, Naples, Italy.
Wictor C SzymanskiUniversity of Groningen, Groningen, The Netherlands.
Nick van der MeulenPaul Scherrer Institute, Villigen, Switzerland.
Frederik CleerenKatholieke Universiteit, Leuven, Belgium.
Ralf SchirrmacherMedical Isotope and Cyclotron Facility, Affiliated member Chemistry and Pharmacy, University of Alberta, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Hua YangTRIUMF, Vancouver, BC, Canada.
Eduardo SavioUruguayan Center for Molecular Imaging (CUDIM), Montevideo, Uruguay.
Naoual BentalebNational Center for Nuclear Energy, Science and Technology (CNESTEN), Rabat, Morocco.
Marcela ZubillagaUniversity of Buenos Aires, Buenos Aires, Argentina.
Ivis F Chaple GoreUniversity of Tennessee, Knoxville, USA.
Mickaël BourgeoisNantes University Hospital - Nuclear Medicine Department, Nantes, France.
Archana MukherjeeBhabha Atomic Research Centre & Homi Bhabha National Institute, Mumbai, India.
Juan PellicoInstitute of Materials Science of Barcelona (ICMAB-CSIC), Barcelona, Spain.
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Faculty of Chemistry and Food Chemistry, School of Science, Helmholtz-Zentrum Dresden- Rossendorf (HZDR), Technical University Dresden (TUD), Dresden, Germany. k.kopka@hzdr.de.ORCID http://orcid.org/0000-0003-4846-1271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. MAIN BODY: This selection of highlights provides commentary on 18 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacy

Identifiers

PMID41042435
PMCPMC12495004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.